InPen communicates with a mobile app, which assists in dose calculations and tracking. Credit: © 2024 Medtronic.

Medtronic has received clearance from the US Food and Drug Administration (FDA) for its new InPen app, paving the way for introducing its Smart multiple daily injection (MDI) system.

The system offers personalised and real-time insights for individuals managing diabetes through MDI therapies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It combines the company’s InPen smart insulin pen with its Simplera continuous glucose monitor (CGM), a disposable, all-in-one device.

The MDI system is poised to be the first on the market to offer recommendations for correcting missed or inaccurate insulin doses.

For diabetic individuals, taking insulin injections before meals is crucial to maintain glucose levels and prevent post-meal blood sugar spikes. Despite their importance, it is estimated that one out of three doses are missed regularly.

The Smart MDI system’s ‘Missed Dose alert’ aims to reduce these occurrences, thereby mitigating the risk of diabetes-related complications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Medtronic plans to initially roll out the Smart MDI system to existing standalone CGM and InPen customers, with a broader commercial launch to follow.

In September 2023, the company announced the CE mark approval for the Simplera CGM. The no-fingerstick sensor does not require additional tape and is compatible with iOS and Android platforms, designed for individuals aged two years and older.

Using Bluetooth technology, InPen communicates with a mobile app, which assists in dose calculations and tracking. The app also includes a missed meal dose identification feature.

The app is said to determine the optimal dose of insulin based on glucose levels, carbohydrate intake, and insulin already active in the body, thereby helping to manage diabetes without the use of a pump.

Its precision allows for dosage decisions in half-units and enables automatic logging of doses, and reminders for insulin administration while providing insights into how diet and activity affect blood sugar levels.